| RNA-LPX (Lipoplex®) |
RNA-lipoplexes |
DC maturation, T cell response |
Phase I (2016) |
|
[82] |
| MRX34 |
miRNA-34a-loaded liposome |
Downregulation of immune evasion tumor genes |
Phase I (2016) |
|
[183] |
| mRNA-4157 |
mRNA-4157 encapsulated in Lipids |
induce neoantigen specific T cells and associated anti-tumor responses. |
Phase I (2019) |
|
[184] |
| Ferumoxytol (Ferahem®) |
Iron oxide nanoparticles (IONP) |
M2 Macrophage polarization to M1-like |
|
Yes, for anemia and kidney diseases |
[185] |
| PTX-LDE |
Paclitaxel-loaded lipid core NPs |
DC maturation |
Phase II (2017) |
|
[186,187] |
| Anti-EGFR-IL-dox |
Doxorubicin-loaded anti-EGFR immunoliposomes |
Block EGFR-mediated growth signaling and induce immunogenic cell death |
Phase II (2016) |
|
NCT02833766 |
| JVRS-100 |
Cationic liposome incorporating plasmid DNA complex |
Immune system stimulation |
Phase I (2016) |
|
NCT00860522 |
| NBTXR3 |
Hafnium oxide nanoparticles in combination with anti-PD1 |
Enhance tumor cell death via electron production, induce immunogenic cell death leading to activation of the immune system |
Phase I (2019) |
|
[188], NCT03589339
|
